Dulaglutid (3) – Trulicity®
Diabetes mellitus type 2, ≥ 10 years
Characteristics
| Start date | 01.04.2023 – Marketing authorisation: 06.03.2023 |
|---|---|
| Resolution | 21.09.2023 |
| INN | Dulaglutid |
| Brand name | Trulicity® |
| Pharm. company | Lilly Deutschland GmbH |
| G-BA Procedure ID | D-918 |
| ATC code | A10BJ05 GLP-1 analogues (A10BJ) |
| Therapeutic area | Metabolic diseases |
| Reason for procedure | New therapeutic indication |
| Specialty | ACT change |
Studies and Results
Children and adolescents aged between 10 and 17 with type 2 diabetes mellitus who do not achieve adequate blood glucose control with their current drug therapy, consisting of at least one blood glucose-lowering medicinal product in addition to diet and exercise
- The additional benefit is not proven.
- Overall, on the basis of the study presented, no conclusions can be drawn regarding the additional benefit of dulaglutide compared with the appropriate comparator therapy.
- Conclusion
- On the whole, no conclusions can be drawn from the study presented regarding the additional benefit of dulaglutide compared with the appropriate comparator therapy. An additional benefit is therefore not proven.
Courtesy translation only, please refer to the German original.
Associated procedures
| Dulaglutid (3) | Trulicity® | Lilly Deutschland GmbH | Diabetes mellitus type 2, ≥ 10 years | 640–710 | 100% additional benefit not proven | |
| Dulaglutid (2) | Trulicity® | Lilly Deutschland GmbH | Diabetes mellitus type 2 | 2,108,000 | 31% Hint for minor additional benefit | |
| Dulaglutid (1) | Trulicity® | Lilly Deutschland GmbH | Diabetes mellitus type 2 |
0
1,705,500–1,905,500 |
31% Hint for minor additional benefit repealed |
<< List of all resolutions